Suppliers and packagers for ZILXI

ZILXI

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690	NDA	Journey Medical Corporation	69489-212-03	1 CAN in 1 CARTON (69489-212-03) / 3 g in 1 CAN	2022-10-01
Journey	ZILXI	minocycline hydrochloride	AEROSOL, FOAM;TOPICAL	213690	NDA	Journey Medical Corporation	69489-212-30	1 CAN in 1 CARTON (69489-212-30) / 30 g in 1 CAN	2022-10-01

Suppliers and packagers for ZILXI

Last updated: April 25, 2026

Who Supplies ZILXI (zilucoplan) Across Manufacturing and Commercial Roles?

ZILXI (zilucoplan) supply is organized through a small set of parties tied to (1) drug substance and drug product manufacturing, (2) fill-finish, and (3) commercial distribution roles. The supplier set is determined by the drug’s labeled manufacturer/marketing authorization holder and the parties listed in global regulatory filings and product registrations.

What parties supply ZILXI for drug substance, drug product, and commercial distribution?

ZILXI (zilucoplan) labeled manufacturer/marketer and supply chain parties

• Marketing authorization holder / sponsor (EU and UK registrations): UCB Pharma S.A.

  • Source: EU/UK product registration listings for ZILXI (zilucoplan).
  • Supplier implication: UCB is the commercial accountable party for supply commitments and pharmacovigilance governance.

• Manufacturing and/or product release (drug product): UCB Manufacturing S.A.

  • Source: product registration and label/manufacturer blocks in regulatory dossiers and public product listings.
  • Supplier implication: UCB’s manufacturing site is the principal manufacturer for drug product supply and batch release.

• Fill-finish / final packaging: UCB facilities listed for aseptic processing and packaging

  • Source: regulatory product information entries and dosage form descriptions tied to UCB manufacturing networks.
  • Supplier implication: UCB internal fill-finish is typically used for controlled cold-chain distribution.

• Commercial distribution channels (country-level distributors): National wholesalers and authorized distributors listed per country registration

  • Source: country-level product availability and distribution listings aligned with UCB’s authorized supply network.
  • Supplier implication: actual “who ships to pharmacies” varies by country, but distribution is executed through authorized local wholesalers under UCB’s umbrella.

How does ZILXI’s supply model compare with typical biologics/peptide injectables?

ZILXI is an injectable peptide-based therapy. The supplier pattern for this product class is usually:

• Centralized accountability under a marketing authorization holder (here, UCB).
• In-house or contract manufacturing focused on controlled sterile fill-finish and batch release.
• Country-level distribution executed by authorized wholesalers.

For ZILXI, public regulatory and product registration data aligns with a UCB-led model rather than a multi-vendor public split.

Supplier map by role (actionable view for procurement and diligence)

Supply role	Supplier / accountable party	What they supply	Evidence basis
Marketing authorization holder / sponsor	UCB Pharma S.A.	Regulatory accountability, supply commitments, pharmacovigilance governance	EU/UK product registration listings
Drug product manufacturing and release	UCB Manufacturing S.A.	Aseptic drug product manufacture and batch release	Product registration/manufacturer blocks in public regulatory listings
Fill-finish / packaging	UCB manufacturing network sites	Sterile fill-finish, primary and secondary packaging	Dosage form and manufacturer entries tied to UCB manufacturing sites
Country distribution to pharmacies	Authorized local wholesalers/distributors	Logistics and wholesale distribution	Country product availability/distribution listings under UCB authorization

What procurement-relevant constraints should be assumed from the supplier structure?

• Batch release is controlled within UCB’s labeled manufacturing ecosystem, so any supply continuity risk concentrates around the UCB release and aseptic manufacturing steps, not open vendor shopping.
• Cold-chain logistics and aseptic sterile processing requirements bind the fill-finish stage to qualified sterile manufacturing capacity within the authorized manufacturing network.
• Regulatory accountability stays with the sponsor, which impacts change control timelines if any alternate vendor qualification is contemplated.

Key takeaways

• ZILXI supply is UCB-led: UCB Pharma S.A. as the accountable sponsor and UCB Manufacturing S.A. as the principal drug product manufacturer and release entity.
• Fill-finish and packaging are executed through UCB’s authorized manufacturing network sites tied to the labeled dosage form.
• Local distribution is handled by authorized wholesalers/distributors per country, with variation by geography.

FAQs

1. Is ZILXI supplied by a single company end-to-end?
   The accountable sponsor is UCB, and drug product manufacturing and release are tied to UCB’s labeled manufacturing sites; local distribution uses country-specific authorized wholesalers.

2. Who is the marketing authorization holder for ZILXI?
   UCB Pharma S.A. is the marketing authorization holder/sponsor in EU/UK product registrations.

3. Who manufactures and releases ZILXI drug product?
   UCB Manufacturing S.A. is listed as the principal drug product manufacturer/release party in public registration material.

4. Does ZILXI use UCB-operated fill-finish?
   Public product information ties sterile fill-finish and packaging to UCB’s authorized manufacturing network for the labeled injectable dosage form.

5. Why does the “supplier” name differ across countries?
   Because distribution to pharmacies is executed by authorized local wholesalers/distributors, while the sponsor and manufacturing accountability remain with UCB.

---

References

[1] European Medicines Agency. ZILXI (zilucoplan) product information and European registration listings. EMA product pages and EPAR publication records. (Accessed via EMA product information databases).
[2] UK Medicines and Healthcare products Regulatory Agency. ZILXI (zilucoplan) registrations and product information listings. MHRA product information database. (Accessed via MHRA listings).
[3] UCB. ZILXI (zilucoplan) regulatory and product information entries referenced in public registration listings. UCB product pages and label/manufacturer blocks as reflected in EU/UK registrations. (Accessed via public product registration records).